Jounce Therapeutics, Inc. (NASDAQ:JNCE) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $12.50 and last traded at $12.50, with a volume of 46,509 shares trading hands. The stock had previously closed at $12.91.
A number of brokerages have recently commented on JNCE. Zacks Investment Research lowered shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Cowen and Company reaffirmed a “buy” rating on shares of Jounce Therapeutics in a research report on Friday, June 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $23.67.
The stock has a 50-day moving average of $13.20 and a 200-day moving average of $19.40. The firm has a market capitalization of $458.87 million and a PE ratio of 528.89.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. The business had revenue of $20.29 million during the quarter, compared to analyst estimates of $19.94 million. During the same quarter last year, the firm earned ($7.23) EPS. On average, equities research analysts expect that Jounce Therapeutics, Inc. will post ($0.62) EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Teachers Advisors LLC boosted its stake in shares of Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after buying an additional 2,347 shares during the period. ARK Investment Management LLC boosted its position in shares of Jounce Therapeutics by 558.9% in the second quarter. ARK Investment Management LLC now owns 11,932 shares of the company’s stock valued at $167,000 after buying an additional 10,121 shares during the last quarter. Nationwide Fund Advisors boosted its position in shares of Jounce Therapeutics by 203.3% in the second quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock valued at $168,000 after buying an additional 8,007 shares during the last quarter. Alliancebernstein L.P. purchased a new position in shares of Jounce Therapeutics during the second quarter valued at approximately $177,000. Finally, Teachers Retirement System of The State of Kentucky boosted its position in shares of Jounce Therapeutics by 180.0% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 12,600 shares of the company’s stock valued at $177,000 after buying an additional 8,100 shares during the last quarter. Institutional investors and hedge funds own 40.83% of the company’s stock.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.
What are top analysts saying about Jounce Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jounce Therapeutics Inc. and related companies.